Multinational Observational Study to Understand Insulin Treatment Intensification: Japanese Subgroup Analysis of the MOSAIc Study.
Diabetes mellitus
HbA1c
Insulin
Japan
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
02
09
2021
accepted:
15
12
2021
pubmed:
7
1
2022
medline:
7
1
2022
entrez:
6
1
2022
Statut:
ppublish
Résumé
MOSAIc was a multinational, non-interventional, prospective, observational cohort study designed to provide an understanding of the specific challenges associated with intensification of initial insulin therapy in patients with type 2 diabetes mellitus (T2DM). We present a sub-analysis of Japanese patients from MOSAIc, with data analyzed longitudinally over 2 years, to provide insight on how T2DM treatment is intensified. Japanese patients with T2DM receiving any insulin therapy for at least 3 months were eligible for study inclusion. Baseline and clinical data were collected during an initial baseline visit and during four subsequent prospective visit windows (within ± 3 months) at 6, 12, 18, and 24 months. Treatment intensification was defined as addition of new insulin, increase in insulin dosage (1-unit change or 10% compared with the previous visit), increase in insulin injection frequency, and/or addition of non-insulin antihyperglycemic agents. Of 116 Japanese patients who completed the study, 50.0% (n = 58) received treatment intensification. Baseline characteristics of patients with treatment intensification included a longer duration of diabetes, higher incidence of baseline microvascular complications, and higher HbA1c compared to those without intensification. There was no significant difference in HbA1c change from baseline between the two groups at any post-baseline visit. Insulin intensification accounted for 61.2% of treatment changes, with non-insulin-related intensification accounting for 36.2% of treatment changes. An increase in insulin dose was the most frequent treatment change (51.7%), followed by the addition of new insulin (22.4%), and an increase in insulin injection frequency (6.9%). Real-world data from Japanese patients with T2DM who received treatment intensification showed that an increase in insulin dose and the addition of new insulin were the most frequent treatment intensification methods. HbA1c was maintained through 2 years of treatment. NCT01400971, ClinicalTrials.gov.
Identifiants
pubmed: 34988917
doi: 10.1007/s13300-021-01195-8
pii: 10.1007/s13300-021-01195-8
pmc: PMC8873337
doi:
Banques de données
ClinicalTrials.gov
['NCT01400971']
Types de publication
Journal Article
Langues
eng
Pagination
265-274Informations de copyright
© 2022. The Author(s).
Références
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.
doi: 10.2337/diacare.27.5.1047
Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129–40.
doi: 10.1001/jama.2009.726
American Diabetes Association. Standards of medical care in diabetes-2019 abridged for primary care providers. Clin Diabetes. 2019;37:11–34.
doi: 10.2337/cd18-0105
Meece J. Basal insulin intensification in patients with type 2 diabetes: a review. Diabetes Ther. 2018;9:877–90.
doi: 10.1007/s13300-018-0395-3
Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.
doi: 10.2337/dc08-9025
Downie M, Kilov G, Wong J. Initiation and intensification strategies in type 2 diabetes management: a comparison of basal plus and premix regimens. Diabetes Ther. 2016;7:641–57.
doi: 10.1007/s13300-016-0199-2
Meneghini LF. Intensifying insulin therapy: what options are available to patients with type 2 diabetes? Am J Med. 2013;126:S28-37.
doi: 10.1016/j.amjmed.2013.06.011
Mosenzon O, Raz I. Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs. Diabetes Care. 2013;36(Suppl 2):S212–8.
doi: 10.2337/dcS13-2007
Polinski JM, Curtis BH, Seeger JD, Choudhry NK, Zagar A, Shrank WH. Rationale and design of the multinational observational study assessing insulin use: the MOSAIc study. BMC Endocr Disord. 2012;12:20.
doi: 10.1186/1472-6823-12-20
Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673–9.
doi: 10.2337/diacare.28.11.2673
Polonsky WH, Arsenault J, Fisher L, et al. Initiating insulin: how to help people with type 2 diabetes start and continue insulin successfully. Int J Clin Pract. 2017;71:e12973.
doi: 10.1111/ijcp.12973
Stuckey H, Fisher L, Polonsky WH, et al. Key factors for overcoming psychological insulin resistance: an examination of patient perspectives through content analysis. BMJ Open Diabetes Res Care. 2019;7:e000723.
doi: 10.1136/bmjdrc-2019-000723
Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl. 2009;63:6–10.
doi: 10.1111/j.1742-1241.2009.02176.x
Polinski JM, Kim SC, Jiang D, et al. Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIc). BMC Endocr Disord. 2015;15:46.
doi: 10.1186/s12902-015-0044-z
Matsuba I, Sawa T, Kawata T, et al. Cross-national variation in glycemic control and diabetes-related distress among East Asian patients using insulin: results from the MOSAIc study. Diabetes Ther. 2016;7:349–60.
doi: 10.1007/s13300-016-0178-7
Ishii H, Terauchi Y, Jinnouchi H, Taketsuna M, Takeuchi M, Imaoka T. Effects of insulin changes on quality of life and glycemic control in Japanese patients with type 2 diabetes mellitus: the insulin-changing study intending to gain patients’ insights into insulin treatment with patient-reported health outcomes in actual clinical treatments (INSIGHTs) study. J Diabetes Investig. 2013;4:560–70.
doi: 10.1111/jdi.12086
Araki E, Goto A, Kondo T, et al. Japanese clinical practice guideline for diabetes 2019. J Diabetes Investig. 2020;11:1020–76. https://doi.org/10.1007/s13340-020-00439-5 .
doi: 10.1007/s13340-020-00439-5
pubmed: 33021749
pmcid: 7378414